艾伯维(ABBV.US)1类新药国内报上市

智通财经10-14

智通财经APP获悉，10月13日，CDE官网显示，艾伯维(ABBV.US)注射用E型肉毒毒素(TrenibotE)上市申请获受理，注册分类为1类。根据公开资料和临床试验进展，Insight数据库推测适应症为中度至重度眉间纹。截图来源：CDE官网TrenibotE是同类首创的E型肉毒神经毒素，2025年4月，艾伯维向FDA提交了该产品的首个上市申请，此申请得到来自2100多名接受TrenibotE...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2575234152?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-10-14 08:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575234152","market":"hk","top_or_hot":-1,"title":"艾伯维(ABBV.US)1类新药国内报上市","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，10月13日，CDE官网显示，艾伯维(ABBV.US)注射用E型肉毒毒素(TrenibotE)上市申请获受理，注册分类为1类。根据公开资料和临床试验进展，Insight数据库推测适应症为中度至重度眉间纹。截图来源：CDE官网TrenibotE是同类首创的E型肉毒神经毒素，2025年4月，艾伯维向FDA提交了该产品的首个上市申请，此申请得到来自2100多名接受TrenibotE...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1354568.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>艾伯维(ABBV.US)1类新药国内报上市</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n艾伯维(ABBV.US)1类新药国内报上市\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-14 08:12 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1354568.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，10月13日，CDE官网显示，艾伯维(ABBV.US)注射用E型肉毒毒素(TrenibotE)上市申请获受理，注册分类为1类。根据公开资料和临床试验进展，Insight数据库推测适应症为中度至重度眉间纹。截图来源：CDE官网TrenibotE是同类首创的E型肉毒神经毒素，2025年4月，艾伯维向FDA提交了该产品的首个上市申请，此申请得到来自2100多名接受TrenibotE...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1354568.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B3PB1722.GBP","symbol_name":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) INC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1354568.html","article_id":"2575234152","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575234152","pubTimestamp":1760400754,"columns":[{"name":"产品发布","id":31,"label_key":"productRelease"}],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，10月13日，CDE官网显示，艾伯维注射用E型肉毒毒素上市申请获受理，注册分类为1类。根据公开资料和临床试验进展，Insight数据库推测适应症为中度至重度眉间纹。III期研究的所有主要和次要终点均已达到，给药后8小时即可快速起效，且疗效持续时间为2-3周。此外，无论是作为单次治疗还是最多连续三次治疗，TrenibotE的治疗中出现的不良事件与安慰剂相似。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00B3PB1722.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) INC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","BK4550":"红杉资本持仓","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","LU0545039389.USD":"BGF GLOBAL EQUITY INCOME \"A2\" ACC","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","LU2129689605.HKD":"FRANKLIN GLOBAL INCOME \"A\" (HKD) INC","SG9999015978.USD":"利安颠覆性创新基金A","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU0882574055.USD":"富达全球健康医疗A ACC","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","LU0861579265.USD":"联博低波幅策略股票基金A","LU0122379950.USD":"贝莱德世界健康科学A2","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","BK4581":"高盛持仓","LU0234572021.USD":"高盛美国核心股票组合Acc","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","BK4585":"ETF&股票定投概念","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","LU0949170772.SGD":"Blackrock Global Equity Income A6 SGD-H","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","ABBV":"艾伯维公司","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC"},"translate_title":"AbbVie (ABBV.US) Class 1 new drug is reported for listing in China","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABBV":1.5},"content_text":"智通财经APP获悉，10月13日，CDE官网显示，艾伯维(ABBV.US)注射用E型肉毒毒素(TrenibotE)上市申请获受理，注册分类为1类。根据公开资料和临床试验进展，Insight数据库推测适应症为中度至重度眉间纹。截图来源：CDE官网TrenibotE是同类首创的E型肉毒神经毒素，2025年4月，艾伯维向FDA提交了该产品的首个上市申请，此申请得到来自2100多名接受TrenibotE治疗患者的临床研究数据的支持，其中包括两项评估TrenibotE治疗中度至重度眉间纹的关键性III期临床研究(M21-500和M21-508)以及一项III期开放标签安全性研究(M21-509)。III期研究的所有主要和次要终点均已达到，给药后8小时即可快速起效(最早评估时间)，且疗效持续时间为2-3周。此外，无论是作为单次治疗还是最多连续三次治疗，TrenibotE的治疗中出现的不良事件与安慰剂相似。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2575234152","isCrawlerRequest":true}